On February 4, 2021 Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin", TSE: 4151) reported that it will make changes to its organization as of April 1, 2021 (Press release, Kyowa Hakko Kirin, FEB 4, 2021, View Source [SID1234574596]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Outline of the changes:
1) Strategic Product Planning Department will be split into the new Global Product Strategy Department and Product Strategy Department.
2) The Research Unit and the Development Unit will be newly established. Under the Research Unit, a new management office, research laboratories and analysis center will be established to take the place of the current Open Innovation Department, research functions of the Category R&D Units, and the Research Functions Unit. Under the Development Unit, a new management office will be established to take the place of the development functions of the current Category R&D Units. Current organizations including the Clinical Development Center, the Biometrics Department and the Development Coordination Department will be placed under the Development Unit.
3) A Digital Sales Promotion office will be newly established within the Sales & Marketing Division.
4) The branches within the Sales & Marketing Division will be reorganized from the current 13 offices to 11.
Purpose of the organizational changes:
1) By separating the Japan and global product strategy formulation and promotion functions, enable the quick execution of business operations and high level decisions within the scope of the management responsibilities of each new department.
2) By shifting from a therapeutic area based organization to a function-based organization, promote cooperation in research and development functions, and guarantee quicker decision making, clearer responsibilities and the agile, flexible allocation of resources.
3) As part of the digital transformation, establish a framework for strengthening data governance in the sales function and the analytics function, and promote a digital shift in the provision of information to medical institutions and related business operations.
4) By merging the branch offices located in close proximity (Kita-Kanto / Koshinetsu and Chugoku / Shikoku), optimize the support for sales activities and realize more efficient branch office operations.